Many women with cancer missing fertility risk info, services

Share this article:

Few women of childbearing age who are diagnosed with cancer are taking steps to preserve their fertility during treatment, and sociodemographic health disparities likely affect access to fertility preservation services, according to recent study findings.

A total of 1,041 women who had been diagnosed with leukemia, Hodgkin disease, non-Hodgkin lymphoma, breast cancer, or GI cancer from 1993 to 2007, when the patients were 18 to 40 years old, responded to a retrospective survey on demographic information and reproductive health history. Of the respondents, 918 reported undergoing treatment that had the potential to affect fertility: chemotherapy, pelvic radiation, pelvic surgery, or bone marrow transplant.

Overall, only 4% of women pursued fertility preservation, but those rates had increased over time: Whereas just 1% of these patients pursued fertility preservation in 1993, 6% did so in 2005 and 10% did so in 2007. Nearly two-thirds (61%) of the women stated that their oncology team had counseled them on the fertility risks of cancer treatment.

Multivariate analyses of the responses revealed that the women who were childless, younger, Caucasian, heterosexual, and college graduates were more likely than other participants to receive counseling regarding the fertility risks posed by cancer treatment or to preserve fertility before cancer treatment.

“Although awareness of fertility preservation has improved in the past decade, an unmet need remains for reproductive health counseling and fertility preservation in reproductive-age women diagnosed with cancer,” concluded study authors Mitchell P. Rosen, MD, of the University of California, San Francisco, and colleagues, in their report for Cancer.


Share this article:
You must be a registered member of ONA to post a comment.

Next Article in Web Exclusives

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Calcium isotope analysis predicts myeloma progression

Researchers believe that a staple of Earth science research can be used in biomedical settings to predict the course of disease.

Biomarker for aggressive, basal-like breast cancer identified

A biomarker strongly linked to basal-like breast cancer has been identified.

Tumor suppressor mutations alone do not explain deadly cancer

Although mutations in a gene dubbed the "guardian of the genome" are recognized as being associated with more aggressive cancers, evidence suggests that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities.